Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079586 | 0.88 | S1PR1 (0.46) | SMN1; SMN2 | |
| SCHEMBL24599224 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EHPGDGAACYP2D6 | |
| SCHEMBL23139484 | 0.78 | S1PR1 (0.59) | SMN1; SMN2GAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23139488 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EHPGD | |
| SCHEMBL9633496 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDMAPT | |
| SCHEMBL2240760 | 0.75 | NOTUM (0.49) | SMN1; SMN2KDM4EHPGDGAANPC1 | |
| SCHEMBL7217455 | 0.72 | LPAR1 (0.35) | GAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23974729 | 0.71 | GAA (0.54) | SMN1; SMN2GAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17014550 | 0.71 | GAA (0.58) | GAAMAPT | |
| SCHEMBL9609808 | 0.70 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EHPGDGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9409908-B2 | Dihydropyridone p1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | SMN1; SMN2 3512/4885KDM4E 776/4885HPGD 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.